Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

The Italian Global Series Festival has launched with Evangeline Lilly and Adjoa Andoh winning awards and Bille August on the ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 71 trades. If we consider the specifics of each ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other low risk stocks. Risk is a key consideration in investing and portfolio management ...

March 12 (Reuters) - U.S. drugmakers Johnson & Johnson (JNJ.N), opens new tab and Eli Lilly (LLY.N), opens new tab increased spending on security for their top executives in 2024, citing increased ...

The weight loss potential is not exactly there to match the likes of Eli Lilly’s tirzepatide or Novo Nordisk’s CagriSema which has an amylin analog as a “performance enhancer” on top of ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best quality stocks to invest in now. Tom Lee, co-founder of Fundstrat Global Advisors ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track to file ...